A new inflection point





10 February 2017



Important notice



This presentation contains statements with respect to the financial condition, results of operations and business of RB (the "Group") and certain of the plans and objectives of the Group that are forward-looking statements. Words such as 'intends', 'targets', or the negative of these terms and other similar expressions of future performance or results, and their negatives, are intended to identify such forward-looking statements. In particular, all statements that express forecasts, expectations and projections with respect to future matters, including targets for net revenue, operating margin and cost efficiency, are forward-looking statements. Such statements are not historical facts, nor are they guarantees of future performance.

By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements, including many factors outside the Group's control. Among other risks and uncertainties, the material or principal factors which could cause actual results to differ materially are: the general economic, business, political and social conditions in the key markets in which the Group operates; the ability of the Group to manage regulatory, tax and legal matters, including changes thereto; the reliability of the Group's technological infrastructure or that of third parties on which the Group relies; interruptions in the Group's supply chain and disruptions to its production facilities; the reputation of the Group's global brands; and the recruitment and retention of key management.

These forward-looking statements speak only as of the date of this presentation. Except as required by any applicable law or regulation, the Group expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Group's expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

No statement in this presentation is or is intended to be a profit forecast or to imply that the earnings of RB or Mead Johnson for the current or future financial years will necessarily match or exceed the historical or published earnings of RB or Mead Johnson.

Any information contained in this presentation on the price at which shares or other securities in RB have been bought or sold in the past, or on the yield on such shares or other securities, should not be relied upon as a guide to future performance.

Terms defined in the announcement made by RB on the date of this presentation have the same meaning in this presentation.



Rakesh Kapoor Chief Executive Officer



Our vision

is a world where people are healthier and live better

Our purpose

is to make a difference by giving people innovative solutions for healthier lives and happier homes

Healthier Lives, Happier Homes – a compelling purpose





betterbusiness









Health Relief Health Nutrition Health Wellness Hygiene Health Hygiene Home Home

Mucinex



































7 of our top 10 Powerbrands focus on healthier lives



Consumer health means enabling children to have the best start to their lives





Mead Johnson – a company with a compelling purpose







To give children the best start in life

Core beliefs

Good early life nutrition supports lifelong health

Informed decisions: access to information helps parents and paediatricians make better decisions

Empowering women: working mothers trust infant formula to support their child's nutritional well-being

Built on a century of medical science





Founded by Edward
Mead Johnson Sr
over 100 years ago
after leaving Johnson
& Johnson





Helping People Lead Healthier Lives From the Beginning



In a category with a strong medical heritage

A consumer health business that is strategically compelling



Fits our criteria of consumer health







Enables consumers to lead healthier and better lives

Strong scientific and medical heritage

~90% increase to our consumer health business

65% increase to our developing market presence (China #2 Powermarket)

Structurally attractive category: worth ~\$46bn, expected to grow at 3-5% in the medium to long term

Structurally attractive category



Urbanisation and economic growth

Women in the work force

Special nutritional needs

Increasing spend on premium nutrition

China – changes to one child policy

Structurally attractive company



Enfa #1 global franchise









Big head no tail

~80%

Enfa family of brands as a proportion of net sales

Large developing market presence

2/3_{rds}

of net sales from developing markets



Our combination An opportunity to bring the best of both

We understand the world of mums & babies...





80 years' expertise in hygiene. Enduring interest in protecting newborns and infants from infection

8 million new mothers reached with hygiene education every year

40 countries in which we work with partners to reach and teach new mums to help them keep their family healthy

...and innovate for the health and wellbeing of children









Strepsils Children 6+

Lozenges soothe little sore throats. Strawberry flavour, with no artificial colours & sugar free

Gaviscon Infant

Helps prevent reflux in children

Airborne Kids

Delicious fruit flavoured vitamin C for kids, providing real immune support

NOW a unique opportunity to do more in the pursuit of healthier lives...





















What Mead Johnson brings...





What RB brings...





Together we bring the best of both companies....



Respected healthcare professional relationships	Scale and infrastructure across China and other developing markets	Operational agility, performance management
Strong R&D, regulatory and quality capabilities	Consumer at heart	Consumer centric innovation and scaling global brands
Deep understanding of new mums and trusted relationships	e-commerce expertise and potential access for Mead Johnson to new markets	Global supply structure and distribution to drive economies of scale

betterbusiness

Healthier lives. Happier homes.





Leadership in this category comes with additional responsibility



Safety
Quality
Compliance
"non-negotiable"

Science-based innovation

Innovation backed by ethical marketing

Quality specifications

Meet or exceed all regulatory and safety requirements




Quality assurance and control



Underpins the trust of mothers and doctors

First we need to learn from each other







Adrian Hennah Chief Financial Officer

Transaction summary





Consideration

All cash offer of \$90 per share with an equity value of \$16.6bn and enterprise value of \$17.9bn

Represents a 29% premium to price on 1 February 2017 or 24% premium to 30-day VWAP

Enterprise value multiple of 17.4x 2016 EBITDA or 14.0x 2016 EBITDA including run-rate cost savings



Shareholder returns

ROIC projected to exceed RB cost of capital by year 5

Accretive to adjusted diluted EPS in the first full year and double-digit accretive by year 3

Dividend policy maintained at about 50% of adjusted net income



Economic rationale

Attractive category

Mead Johnson is a global leader

As part of RB, prospects are enhanced

Estimated annual cost savings of £200m by end of year 3

Transaction summary





Financing

Financed through new fully underwritten debt facilities

Bridge facility expected to be refinanced through the issuance of bonds at or shortly after completion

RB expects to retain a strong investment grade rating



Timing and completion

Transaction is approved by both boards


Represents a class 1 transaction for RB

Completion is subject to RB and Mead Johnson shareholder approvals and regulatory clearances

Expected completion by end of Q3 2017

Historic and future performance





* Constant dollar growth rates

2015 (-2%), 2016 (-3%) *

Cost savings will NOT be focused on core Mead Johnson capabilities



Safety, quality and compliance

Nutritional science and product development

Healthcare professional relationships

Specialist distribution channels

RB will retain the existing strengths of Mead Johnson

Cost savings will be focused on...



Back office

Procurement

Operational rigour

Estimated £200m in annual cost savings by end of third full year Expected £450m one-off costs to achieve the savings

Financing



Fully underwritten debt facilities in place

Bridge facility
expected to be
refinanced through
the issuance of
bonds at or shortly
after completion

Expect to retain a strong investment grade rating

Timing and completion



RB shareholder approval Class 1 transaction

Mead Johnson shareholder approval

Regulatory approval in US, China and other markets

Expected to complete by end of Q3 2017





Rakesh Kapoor Chief Executive Officer

Three types of M&A...









RB's M&A strategy





Strategically compelling



RB better owners



Value creation for shareholders

The acquisition of Mead Johnson will be the next inflection point



Strategically compelling

A structurally attractive category

Mead Johnson – a global leader with #1 global brand franchise

~90% increase to our consumer health business

65% increase to our developing market presence

Combination to make RB better

Strong R&D, quality, regulatory and specialist distribution capabilities

Combined with RB's proven global marketing, innovation and operational strengths

Value creation for shareholders

ROIC projected to exceed RB cost of capital by year 5

Accretive to adjusted diluted EPS in the first full year and double-digit accretive by year 3

Dividend payout policy maintained at about 50% of adjusted net income

Entering new categories creates inflection points in our business







Q&A